Article

Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine.

Aaron Diamond AIDS Research Center, New York, New York, United States of America.
PLoS ONE (Impact Factor: 3.23). 01/2010; 5(1):e8617. DOI: 10.1371/journal.pone.0008617
Source: PubMed

ABSTRACT We conducted a Phase I dose escalation trial of ADVAX, a DNA-based candidate HIV-1 vaccine expressing Clade C/B' env, gag, pol, nef, and tat genes. Sequences were derived from a prevalent circulating recombinant form in Yunnan, China, an area of high HIV-1 incidence. The objective was to evaluate the safety and immunogenicity of ADVAX in human volunteers.
ADVAX or placebo was administered intramuscularly at months 0, 1 and 3 to 45 healthy volunteers not at high risk for HIV-1. Three dosage levels [0.2 mg (low), 1.0 mg (mid), and 4.0 mg (high)] were tested. Twelve volunteers in each dosage group were assigned to receive ADVAX and three to receive placebo in a double-blind design. Subjects were followed for local and systemic reactogenicity, adverse events, and clinical laboratory parameters. Study follow up was 18 months. Humoral immunogenicity was evaluated by anti-gp120 binding ELISA. Cellular immunogenicity was assessed by a validated IFNgamma ELISpot assay and intracellular cytokine staining. ADVAX was safe and well-tolerated, with no vaccine-related serious adverse events. Local and systemic reactogenicity events were reported by 64% and 42% of vaccine recipients, respectively. The majority of events were mild. The IFNgamma ELISpot response rates to any HIV antigen were 0/9 (0%) in the placebo group, 3/12 (25%) in the low-dosage group, 4/12 (33%) in the mid-dosage group, and 2/12 (17%) in the high-dosage group. Overall, responses were generally transient and occurred to each gene product, although volunteers responded to single antigens only. Binding antibodies to gp120 were not detected in any volunteers, and HIV seroconversion did not occur.
ADVAX delivered intramuscularly is safe, well-tolerated, and elicits modest but transient cellular immune responses.
Clinicaltrials.gov NCT00249106.

Download full-text

Full-text

Available from: Patricia Fast, Aug 27, 2015
2 Followers
 · 
177 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: The performance evaluation model for CSMA/CD bus under heavy load is presented. Based on the definition of the critical point of heavy load and the description of difference between the average collision times of users and the system, a Markov transfer matrix of the system state is provided and the mathematical model which is suitable for evaluating the performance of CSMA/CD protocol under heavy load is established. After a comparison with the simulation results, an analytical approximation of the new method is presented and the results show that our model is close to the real system
    TENCON '93. Proceedings. Computer, Communication, Control and Power Engineering.1993 IEEE Region 10 Conference on; 11/1993
  • [Show abstract] [Hide abstract]
    ABSTRACT: The understanding of vacuum arc processes including the cathode and anode phenomena with cold and hot electrodes as well as the processes in interelectrode plasma is presented. In the case of cold electrodes, the current continuity mechanism, the nature of mass loss, spot motion, plasma jet generation in the spots and the cathode potential drop are reviewed. The explosive and gas-dynamical models of cathode spot operation are described. In the case of hot electrodes, the diffuse current continuity mechanism is analyzed. The present state of electrical and plasma characteristics of high current arcs in magnetic fields are discussed
    Discharges and Electrical Insulation in Vacuum, 2000. Proceedings. ISDEIV. XIXth International Symposium on; 02/2000
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Naïve Indian rhesus macaques were immunized with a mixture of optimized plasmid DNAs expressing several SIV antigens using in vivo electroporation via the intramuscular route. The animals were monitored for the development of SIV-specific systemic (blood) and mucosal (bronchoalveolar lavage) cellular and humoral immune responses. The immune responses were of great magnitude, broad (Gag, Pol, Nef, Tat and Vif), long-lasting (up to 90 weeks post third vaccination) and were boosted with each subsequent immunization, even after an extended 90-week rest period. The SIV-specific cellular immune responses were consistently more abundant in bronchoalveolar lavage (BAL) than in blood, and were characterized as predominantly effector memory CD4(+) and CD8(+) T cells in BAL and as both central and effector memory T cells in blood. SIV-specific T cells containing Granzyme B were readily detected in both blood and BAL, suggesting the presence of effector cells with cytolytic potential. DNA vaccination also elicited long-lasting systemic and mucosal humoral immune responses, including the induction of Gag-specific IgA. The combination of optimized DNA vectors and improved intramuscular delivery by in vivo electroporation has the potential to elicit both cellular and humoral responses and dissemination to the periphery, and thus to improve DNA immunization efficacy.
    Vaccine 05/2010; 28(30):4827-36. DOI:10.1016/j.vaccine.2010.04.064 · 3.49 Impact Factor
Show more